Literature DB >> 8219612

A successful liver metastasis model in mice with neuraminidase treated colon 26.

K Okuno1, Y Shirayama, H Ohnishi, K Yamamoto, M Ozaki, T Hirohata, I Nakajima, M Yasutomi.   

Abstract

The aim of this study was to establish a reproducible and quantitative liver metastasis model in mice. The in vitro colon 26 (C-26) cultured cell line was initially taken from an in vivo transplantable C-26 adenocarcinoma tumor mass using the standard enzymatic treatments, collagenase and DNAse. In vitro cultured cells x 10(4) were introduced into the portal vein of syngeneic BALB/c mice to induce liver metastases and, 3 weeks later metastatic foci were found in approximately 50% to 70% of the mice. In contrast, C-26 cells desialylated by neuraminidase (Nase) treatment greatly increased the incidence of hepatic metastases with countable hepatic colonies being found in all mice (100%). This result seems to be related to the liver-characteristic D-galactose receptors, since pre-injection with an excess amount of galactocerebroside completely prevented tumor colonization in the liver. Thus, although we cannot disregard the involvement of other adhesion molecules in this system as yet, our experimental model may become a useful tool for the analysis of hepatic metastases from colon cancer in the future.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219612     DOI: 10.1007/bf00311622

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  12 in total

1.  Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.

Authors:  K Okuno; H Takagi; T Nakamura; Y Nakamura; Z Iwasa; M Yasutomi
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

2.  Carcinoma of the colon with liver metastases. Operative indications and prognosis.

Authors:  J Nielsen; I Balslev; H E Jensen
Journal:  Acta Chir Scand       Date:  1971

3.  The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.

Authors:  S Bengmark; L Hafström
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

4.  Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells.

Authors:  A Raz; L Meromsky; R Lotan
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

5.  Identification and quantification of the rat hepatocyte asialoglycoprotein receptor.

Authors:  A L Schwartz; A Marshak-Rothstein; D Rup; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

6.  Proposed molecular basis of murine tumor cell-hepatocyte interaction.

Authors:  G F Springer; R Cheingsong-Popov; V Schirrmacher; P R Desai; H Tegtmeyer
Journal:  J Biol Chem       Date:  1983-05-10       Impact factor: 5.157

7.  Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.

Authors:  A Goldin; J M Venditti; J S Macdonald; F M Muggia; J E Henney; V T Devita
Journal:  Eur J Cancer       Date:  1981-02       Impact factor: 9.162

Review 8.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

9.  B16 melanoma metastases in mouse liver and lung. I. Localization.

Authors:  K P Dingemans; R van Spronsen; E Thunnissen
Journal:  Invasion Metastasis       Date:  1985

10.  Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody.

Authors:  V Schirrmacher; R Cheingsong-Popov; H Arnheiter
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

View more
  1 in total

1.  What makes cancer stem cell markers different?

Authors:  Uwe Karsten; Steffen Goletz
Journal:  Springerplus       Date:  2013-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.